Clinical Reviews in Allergy & Immunology

, Volume 45, Issue 1, pp 75–86

Aspirin-Intolerant Asthma: A Comprehensive Review of Biomarkers and Pathophysiology


DOI: 10.1007/s12016-012-8340-0

Cite this article as:
Velazquez, J.R. & Teran, L.M. Clinic Rev Allerg Immunol (2013) 45: 75. doi:10.1007/s12016-012-8340-0


Aspirin-exacerbated respiratory disease is a tetrad of nasal polyps, chronic hypertrophic eosinophilic sinusitis, asthma, and sensitivity to aspirin. Unawareness of this clinical condition by patients and physicians may have grave consequences because of its association with near-fatal asthma. The pathogenesis of aspirin-intolerant asthma is not related with an immunoglobin E mechanism, but with an abnormal metabolism of the lipoxygenase (LO) and cyclooxygenase (COX) pathways. At present, a diagnosis of aspirin sensitivity can be established only by provocative aspirin challenge, which represents a health risk for the patient. This circumstance has encouraged the search for aspirin intolerance-specific biomarkers. Major attempts have focused on mediators related with inflammation and eicosanoid regulation. The use of modern laboratory techniques including high-throughput methods has facilitated the detection of dozens of biological metabolites associated with aspirin-intolerant asthma disease. Not surprisingly, the majority of these is implicated in the LO and COX pathways. However, substantial amounts of data reveal the participation of many genes deriving from different ontologies. Biomarkers may represent a powerful, noninvasive tool in the diagnosis of aspirin sensitivity; moreover, they could provide a new way to classify asthma phenotypes.



Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Departamento de Inmunogenética y AlergiaInstituto Nacional de Enfermedades Respiratorias (INER)Mexico CityMexico